title: Effect of spindle checkpoint on Akt2-mediated paclitaxel-resistance in A2780 ovarian cancer cells.
abstract: Recent evidence has suggested that Akt2 plays an important role in the protection of cells from paclitaxel (PTX)-induced apoptosis and control of the cell cycle. In addition, some scholars suggested that the PTX sensitivity depends on a functional spindle assembly checkpoint. In the present study, we investigated the role of the Akt2/Bub1 cross-talking in apoptosis and cell cycle after exposure of the A2780 ovarian cancer cells to paclitaxel (PTX). Recombinant expression plasmid WT-Akt2 was transfected into A2780 cells by lipofectamine2000, and then the expression level of Akt2 gene was detected by using RT-PCR and Western blotting. Cell apoptosis and cell cycle were detected by flow cytometry and Hoechst 33342 staining after treatment with PTX. Moreover, we compared the expression level of Bub1 in different groups by Western blotting. Our study showed that up-regulation of Akt2 contributed to A2780 ovarian cancer cells overriding PTX-induced G(2)/M arrest, and inhibited Bub1 expression. Our findings might shed light on the molecular mechanism of PTX-induced resistance in ovarian cancer and help develop novel anti-neoplastic strategies.
authors.affiliation: Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. fam0522@163.com
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.forename: Yindi
authors.initials: Y
authors.lastname: Bao
authors.forename: Shuangmei
authors.initials: S
authors.lastname: Ye
authors.forename: Danhui
authors.initials: D
authors.lastname: Weng
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
authors.forename: Yunping
authors.initials: Y
authors.lastname: Lu
authors.forename: Ding
authors.initials: D
authors.lastname: Ma
authors.forename: Shixuan
authors.initials: S
authors.lastname: Wang
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D017239:Paclitaxel / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism*; D020239:Receptor Cross-Talk
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C494921:AKT2 protein, human; C584277:BUB1 protein, human; C090464:Bub1 spindle checkpoint protein; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D017239:Paclitaxel
references.citation: Mol Cell Biol. 1994 Dec;14(12):8282-91
references.pmid: 7969164
references.citation: Cancer Treat Rev. 2006 May;32(3):166-79
references.pmid: 16527420
references.citation: Annu Rev Med. 1997;48:353-74
references.pmid: 9046968
references.citation: Cancer Sci. 2008 Sep;99(9):1709-14
references.pmid: 18537980
references.citation: J Cell Sci. 2002 Feb 1;115(Pt 3):575-85
references.pmid: 11861764
references.citation: Cancer Res. 2009 Jan 1;69(1):45-54
references.pmid: 19117986
references.citation: CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
references.pmid: 11814064
references.citation: Cancer Res. 2008 Oct 1;68(19):7923-31
references.pmid: 18829549
references.citation: J Cell Biol. 2001 Jun 11;153(6):1239-50
references.pmid: 11402067
references.citation: Mol Cell Biol. 2002 Nov;22(22):7831-41
references.pmid: 12391152
references.citation: J Cell Sci. 2003 Jul 15;116(Pt 14):2987-98
references.pmid: 12783991
references.citation: Mol Cell. 2003 May;11(5):1201-13
references.pmid: 12769845
references.citation: Cell. 1997 May 30;89(5):727-35
references.pmid: 9182760
references.citation: Cancer Lett. 2008 Mar 8;261(1):108-19
references.pmid: 18171600
references.citation: Leukemia. 2003 Jul;17(7):1263-93
references.pmid: 12835716
references.citation: J Cell Physiol. 2003 Jul;196(1):9-18
references.pmid: 12767037
references.citation: J Cell Biol. 1998 Dec 28;143(7):1775-87
references.pmid: 9864354
references.citation: Cancer Lett. 2009 Jan 18;273(2):257-65
references.pmid: 18842333
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12776-81
references.pmid: 19617567
references.citation: Nat Cell Biol. 2009 Apr;11(4):397-408
references.pmid: 19270695
references.citation: J Clin Invest. 2000 Oct;106(8):1011-20
references.pmid: 11032861
references.citation: Oncogene. 2000 May 4;19(19):2324-30
references.pmid: 10822383
references.citation: Cancer Res. 2004 Apr 1;64(7):2502-8
references.pmid: 15059905
references.citation: Mol Biol Cell. 2006 Mar;17(3):1483-93
references.pmid: 16407408